Clinical Briefings™: An Expert Evaluation of New Data Surrounding Treatments on the Horizon for Cutaneous and Systemic Lupus Erythematosus

Released On
September 11, 2020

Expires On
September 11, 2021

Media Type

Completion Time
60 minutes

Dermatology, Primary Care, Rheumatology


Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

This activity is supported by an educational grant from Biogen.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed toward rheumatologists, internists, dermatologists, specialty NPs and PAs, and primary care physicians engaged in the care of patients with CLE and SLE.

Activity Overview

This online activity is designed to provide a concise and focused overview on an important clinical topic and includes information on the significant unmet medical needs and treatment challenges in the management of patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE). Constant advancement in the understanding of the pathophysiology of CLE and SLE and the discovery of various therapeutic pathways has led to new therapies. Novel biological agents are progressing rapidly toward potentially fulfilling unmet needs in the treatment of CLE and SLE. The engaging multimedia format of this program includes audio commentary from an expert thought leader integrated with text-based elements.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Describe strategies to achieve accurate and early diagnosis of CLE and SLE:
  • Assess clinical trial data on emerging treatment options for patients with CLE and SLE
  • Evaluate the potential impact of emerging and investigational therapies in patients with CLE and SLE


Victoria P. Werth, MD

Department of Dermatology
Professor of Dermatology and Medicine
University of Pennsylvania
Philadelphia, PA

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hours.

Disclosures of Conflicts of Interest

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Victoria P. Werth, MD

  • Grant/Research Support: Celgene, Janssen, Pfizer, Biogen, Gilead, Corbus Pharmaceuticals, Genentech, AstraZeneca, Viela Bio, Syntimmune
  • Consulting: Celgene, Medimmune, Resolve Therapeutics, Genentech, Idera Pharmaceuticals, Janssen, Lilly, Pfizer, Biogen, Bristol Myers Squibb, Gilead, Amgen, Medscape, Nektar Therapeutics, Incyte, EMD Serono, CSL Behring, Principia Biopharma, Chrysalis Biotherapeutics, Viela Bio, argenx, Kyowa Kirin, Regeneron, AstraZeneca, AbbVie, Octapharma, GSK, Cugene, UCB

The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Instructions for Participation/How to Receive Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.